Table 1 Clinical and histopathological characteristics of patients and their respective tumours
All eligible patients n = 34 | Good responders n =17 | Poor responders n =17 | p-value | ||
|---|---|---|---|---|---|
Age | Mean | 58.6 | 58.0 | 59.2 | 0.07 |
Gender | Female | 14 (41%) | 5 (29%) | 9 (53%) | 0.30 |
Male | 20 (59%) | 12 (71%) | 8 (47%) | ||
Number of metastatic sites | 1 | 17 (50%) | 9 (53%) | 8 (47%) | 0.60 |
>1 | 17 (50%) | 8 (47%) | 9 (53%) | ||
WHO PS | 0 | 23 (68%) | 11 (65%) | 12 (71%) | 0.71 |
1 | 11 (32%) | 6 (35%) | 5 (29%) | ||
Site of primary tumour | Colon | 22 (65%) | 11 (65%) | 11 (65%) | 0.90 |
Rectosigmoid | 12 (35%) | 6 (35%) | 6 (35%) | ||
T stage | 1-2 | 4 (12%) | 2 (12%) | 2 (12%) | 0.49 |
3 | 21 (62%) | 12 (71%) | 9 (53%) | ||
4 | 9 (26%) | 3 (18%) | 6 (35%) | ||
N stage | 0 | 9 (26%) | 4 (24%) | 5 (29%) | 0.61 |
1 | 8 (24%) | 4 (24%) | 4 (24%) | ||
2 | 14 (41%) | 9 (53%) | 5 (29%) | ||
Unknown | 3 (9%) | 0 | 3 (18%) | ||
Differentiation grade | Good | 1 (3%) | 1 (6%) | 0 | 0.02 |
Moderate | 23 (68%) | 15 (88%) | 8 (47%) | ||
Poor | 10 (29%) | 1 (6%) | 9 (53%) | ||
Wild-type | 30 (88%) | 16 (94%) | 14 (82%) | 0.29 | |
Mutant | 4 (12%) | 1 (6%) | 3 (18%) | ||
KRAS mutation status | Wild-type | 19 (56%) | 11 (65%) | 8 (47%) | 0.30 |
Mutant | 15 (44%) | 6 (35%) | 9 (53%) | ||
KRAS mutation type | Codon 12 | 14 (93%) | 6 (100%) | 8 (89%) | 0.40 |
Codon 13 | 1 (7%) | 0 | 1 (11%) | ||
PFS (months) | Median (range) | 11.0 (2.3-39.8) | 22.5 (14.8-39.8) | 6.0 (2.3-7.2) | s<0.0001 |